Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free ELVN Stock Alerts

Enliven Therapeutics (ELVN) Financials

Enliven Therapeutics logo
$43.08 -0.48 (-1.10%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$43.20 +0.12 (+0.28%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Enliven Therapeutics

Annual Income Statements for Enliven Therapeutics

This table shows Enliven Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -23 -49 -51 -38 -72 -89 -104
Consolidated Net Income / (Loss)		 -23 -41 -51 -38 -72 -89 -104
Net Income / (Loss) Continuing Operations		 -23 -41 -51 -38 -72 -90 -104
Total Pre-Tax Income 		-23 -41 -51 -38 -72 -90 -104
Total Operating Income		 -24 -42 -51 -39 -84 -105 -120
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 24 42 51 39 84 105 120
Selling, General & Admin Expense		 5.11 9.54 13 7.77 19 24 34
Research & Development Expense		 19 32 38 31 65 81 86
Total Other Income / (Expense), net		 0.65 0.34 0.06 1.13 12 16 16
Interest & Investment Income		 0.58 0.48 0.23 1.13 12 15 16
Other Income / (Expense), net		 0.08 -0.15 -0.18 0.00 -0.02 -0.00 -0.05
Income Tax Expense		 - - 0.00 - 0.00 0.23 0.00
Basic Earnings per Share		 ($33.40) ($49,218,003.53) ($2.37) ($12.05) ($2.01) ($1.89) ($1.83)
Weighted Average Basic Shares Outstanding		 702.46K 13.92M 21.66M 3.12M 35.55M 47.07M 56.66M
Diluted Earnings per Share		 ($33.40) ($49,218,003.53) ($2.37) ($12.05) ($2.01) ($1.89) ($1.83)
Weighted Average Diluted Shares Outstanding		 702.46K 13.92M 21.66M 3.12M 35.55M 47.07M 56.66M
Weighted Average Basic & Diluted Shares Outstanding		 702.46K 13.92M 21.66M 26.23M 41.35M 49.00M 59.80M

Quarterly Income Statements for Enliven Therapeutics

This table shows Enliven Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -21 -19 -23 -20 -23 -23 -29 -25 -20 -30 -24
Consolidated Net Income / (Loss)		 -21 -19 -23 -20 -23 -23 -29 -25 -20 -30 -24
Net Income / (Loss) Continuing Operations		 -21 -19 -23 -20 -23 -23 -29 -25 -20 -30 -24
Total Pre-Tax Income 		-21 -19 -23 -20 -23 -23 -29 -25 -20 -30 -24
Total Operating Income		 -24 -23 -26 -25 -27 -27 -32 -29 -25 -34 -28
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 24 23 26 25 27 27 32 29 25 34 28
Selling, General & Admin Expense		 4.64 4.82 6.02 5.78 5.81 6.17 6.80 7.09 6.87 13 7.14
Research & Development Expense		 20 18 20 19 21 21 25 21 18 21 21
Total Other Income / (Expense), net		 3.48 3.36 3.25 4.65 3.91 3.48 3.15 3.25 4.95 4.62 4.20
Interest & Investment Income		 3.49 3.37 3.25 4.09 3.84 3.72 3.20 3.25 4.95 4.62 4.20
Other Income / (Expense), net		 -0.01 -0.01 -0.00 0.80 0.07 - -0.05 -0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.51) ($0.29) ($0.54) ($0.41) ($0.48) ($0.46) ($0.57) ($0.49) ($0.32) ($0.45) ($0.38)
Weighted Average Basic Shares Outstanding		 41.03M 35.55M 42.05M 48.08M 48.27M 47.07M 50.05M 52.11M 62.09M 56.66M 62.80M
Diluted Earnings per Share		 ($0.51) ($0.29) ($0.54) ($0.41) ($0.48) ($0.46) ($0.57) ($0.49) ($0.32) ($0.45) ($0.38)
Weighted Average Diluted Shares Outstanding		 41.03M 35.55M 42.05M 48.08M 48.27M 47.07M 50.05M 52.11M 62.09M 56.66M 62.80M
Weighted Average Basic & Diluted Shares Outstanding		 41.21M 41.35M 47.04M 47.24M 48.86M 49.00M 49.07M 59.24M 59.35M 59.80M 60.90M

Annual Cash Flow Statements for Enliven Therapeutics

This table details how cash moves in and out of Enliven Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.36 43 0.70 -34 25 24 -25
Net Cash From Operating Activities		 -22 -37 -47 -32 -61 -73 -70
Net Cash From Continuing Operating Activities		 -22 -37 -47 -32 -61 -73 -70
Net Income / (Loss) Continuing Operations		 -23 -41 -51 -38 -72 -89 -104
Consolidated Net Income / (Loss)		 -23 -41 -51 -38 -72 -89 -104
Depreciation Expense		 0.03 0.10 0.10 0.22 0.30 0.32 0.26
Amortization Expense		 -0.02 0.12 0.16 0.00 -4.60 0.42 -0.23
Non-Cash Adjustments To Reconcile Net Income		 0.90 2.23 3.87 4.93 13 20 34
Changes in Operating Assets and Liabilities, net		 0.67 1.51 0.51 0.44 1.40 -4.54 -1.12
Net Cash From Investing Activities		 -24 -17 -1.63 -0.61 -148 -36 -174
Net Cash From Continuing Investing Activities		 -24 -17 -1.63 -0.61 -148 -36 -174
Purchase of Property, Plant & Equipment		 -0.14 -0.02 -0.01 -0.61 -0.15 -0.04 -0.16
Purchase of Investments		 -24 -64 -48 0.00 -268 -351 -447
Sale of Property, Plant & Equipment		 - - 0.00 - - 0.00 0.21
Sale and/or Maturity of Investments		 0.00 48 46 0.00 120 314 273
Other Investing Activities, net		 - - - - 0.00 0.87 0.00
Net Cash From Financing Activities		 44 97 49 -1.80 234 133 219
Net Cash From Continuing Financing Activities		 44 97 49 -1.80 235 133 219
Issuance of Common Equity		 0.00 80 1.82 0.00 161 130 217
Other Financing Activities, net		 0.00 1.02 0.86 -1.80 82 3.63 2.08
Cash Income Taxes Paid		 - - - - 0.00 0.23 0.00

Quarterly Cash Flow Statements for Enliven Therapeutics

This table details how cash moves in and out of Enliven Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -52 26 49 -52 3.75 23 -22 18 -18 -2.84 33
Net Cash From Operating Activities		 -16 -12 -23 -20 -12 -17 -24 -17 -13 -16 -19
Net Cash From Continuing Operating Activities		 -16 -12 -23 -20 -12 -17 -24 -17 -13 -16 -19
Net Income / (Loss) Continuing Operations		 -21 -19 -23 -20 -23 -23 -29 -25 -20 -30 -24
Consolidated Net Income / (Loss)		 -21 -19 -23 -20 -23 -23 -29 -25 -20 -30 -24
Depreciation Expense		 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.08 0.06 0.05 0.01
Amortization Expense		 -1.98 -1.79 -0.66 -0.60 0.71 0.98 -0.05 0.07 -0.31 0.06 0.27
Non-Cash Adjustments To Reconcile Net Income		 3.63 3.13 4.59 4.42 5.18 5.43 6.88 7.81 7.27 13 7.49
Changes in Operating Assets and Liabilities, net		 3.15 5.46 -4.64 -4.38 4.99 -0.51 -2.50 0.31 -0.16 1.22 -3.43
Net Cash From Investing Activities		 -36 39 -18 -34 15 0.73 1.43 -184 -4.06 12 43
Net Cash From Continuing Investing Activities		 -36 39 -18 -34 15 0.73 1.43 -184 -4.06 12 43
Purchase of Property, Plant & Equipment		 -0.02 -0.01 -0.02 -0.00 -0.02 - -0.02 -0.14 0.00 - 0.00
Purchase of Investments		 -76 -41 -57 -121 -57 -117 -59 -240 -72 -76 -66
Sale and/or Maturity of Investments		 40 80 39 77 81 117 61 57 68 88 108
Net Cash From Financing Activities		 -0.43 0.09 90 1.81 1.12 40 0.23 218 -0.37 0.62 10
Net Cash From Continuing Financing Activities		 -0.43 0.65 90 1.81 1.12 40 0.23 218 -0.37 0.62 10
Other Financing Activities, net		 -0.43 0.65 0.27 1.79 1.12 0.45 0.23 1.32 0.09 0.43 10

Annual Balance Sheets for Enliven Therapeutics

This table presents Enliven Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 33 91 94 83 272 326 476
Total Current Assets		 31 90 93 78 266 318 475
Cash & Equivalents		 4.94 48 48 76 100 124 99
Short-Term Investments		 24 41 42 0.00 153 189 364
Prepaid Expenses		 1.72 2.18 2.42 2.22 2.95 4.63 12
Plant, Property, & Equipment, net		 0.44 0.35 0.25 0.89 0.74 0.46 0.03
Total Noncurrent Assets		 2.23 0.09 0.70 4.66 4.97 7.18 1.26
Other Noncurrent Operating Assets		 2.23 0.09 0.70 4.66 4.97 7.18 1.26
Total Liabilities & Shareholders' Equity		 33 91 94 83 272 326 476
Total Liabilities		 4.38 6.41 7.62 10 26 16 17
Total Current Liabilities		 4.20 6.25 7.21 9.72 26 16 17
Accounts Payable		 1.66 1.97 2.36 3.44 0.53 1.34 2.16
Accrued Expenses		 2.54 4.28 4.60 6.28 15 15 14
Total Noncurrent Liabilities		 0.18 0.16 0.41 0.66 0.07 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -49 84 86 73 246 310 460
Total Preferred & Common Equity		 -49 84 86 -77 246 310 460
Preferred Stock		 0.00 0.00 0.00 150 0.00 0.00 0.00
Total Common Equity		 -49 84 86 -77 246 310 460
Common Stock		 5.87 181 234 6.04 400 553 806
Retained Earnings		 -55 -96 -147 -83 -154 -243 -347
Accumulated Other Comprehensive Income / (Loss)		 0.03 0.00 -0.02 0.00 0.14 0.06 0.33

Quarterly Balance Sheets for Enliven Therapeutics

This table presents Enliven Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 59 303 289 274 343 327 305 303 504 491 465
Total Current Assets		 59 298 283 269 337 318 297 294 496 483 463
Cash & Equivalents		 49 292 126 74 149 97 101 102 119 102 132
Short-Term Investments		 6.81 - 152 190 171 216 191 188 371 376 320
Prepaid Expenses		 2.80 5.90 5.31 5.13 6.64 5.68 5.11 4.76 5.12 5.12 11
Plant, Property, & Equipment, net		 0.00 0.85 0.87 0.81 0.68 0.63 0.55 0.40 0.46 0.40 0.02
Total Noncurrent Assets		 0.00 4.01 4.46 4.63 4.90 8.29 7.88 7.85 7.80 7.79 1.70
Other Noncurrent Operating Assets		 0.00 4.01 4.46 4.63 4.90 8.29 7.88 7.85 7.80 7.79 1.70
Total Liabilities & Shareholders' Equity		 59 303 289 274 343 327 305 303 504 491 465
Total Liabilities		 1.82 11 9.51 12 25 22 17 14 15 15 11
Total Current Liabilities		 1.82 11 9.15 12 25 22 17 14 15 15 11
Accounts Payable		 0.77 5.86 2.84 1.49 2.73 1.08 1.02 1.56 2.35 1.43 1.64
Accrued Expenses		 1.05 5.08 6.30 11 12 12 16 12 13 13 9.85
Total Noncurrent Liabilities		 0.00 0.51 0.36 0.21 0.03 0.01 0.00 0.30 0.20 0.10 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 57 291 279 262 318 305 288 288 488 476 453
Total Preferred & Common Equity		 57 291 279 262 318 305 288 288 488 476 453
Preferred Stock		 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 57 291 279 262 318 305 288 288 488 476 453
Common Stock		 235 389 393 397 495 502 508 560 786 793 825
Retained Earnings		 -178 -98 -114 -135 -177 -197 -220 -272 -297 -317 -371
Accumulated Other Comprehensive Income / (Loss)		 -0.00 - -0.11 -0.15 -0.05 -0.14 0.24 -0.02 -0.18 0.22 -0.38

Annual Metrics And Ratios for Enliven Therapeutics

This table displays calculated financial ratios and metrics derived from Enliven Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - 59,347,317.00
DEI Adjusted Shares Outstanding		 - - - - - - 59,347,317.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -1.75
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -17 -29 -36 -27 -58 -73 -84
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -23.78% -23.62% -18.22%
Earnings before Interest and Taxes (EBIT)		 -24 -42 -52 -39 -84 -104 -120
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -42 -51 -39 -88 -103 -120
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -25 -36 -29 -54 -77 -84
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.01 -3.79 -4.25 -2.61 -7.30 -3.65 -3.02
Increase / (Decrease) in Invested Capital		 0.00 -3.80 -0.46 1.64 -4.68 3.65 0.63
Book Value per Share		 ($69.54) $4.85 $3.27 ($2.92) $5.97 $6.34 $7.74
Tangible Book Value per Share		 ($69.54) $4.85 $3.27 ($2.92) $5.97 $6.34 $7.74
Total Capital		 29 84 86 73 246 310 460
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -29 -88 -90 -76 -253 -313 -463
Capital Expenditures (CapEx)		 0.14 0.02 0.01 0.61 0.15 0.04 -0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.48 -4.06 -4.79 -7.50 -13 -11 -4.31
Debt-free Net Working Capital (DFNWC)		 26 84 85 68 240 302 458
Net Working Capital (NWC)		 26 84 85 68 240 302 458
Net Nonoperating Expense (NNE)		 6.58 12 15 11 13 16 20
Net Nonoperating Obligations (NNO)		 -29 -88 -90 -76 -253 -313 -463
Total Depreciation and Amortization (D&A)		 0.01 0.22 0.25 0.22 -4.31 0.74 0.04
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.53) ($51,384,002.37) $0.06 ($2.01) ($1.89) ($1.83)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 17.58M 26.29M 26.29M 35.55M 47.07M 56.66M
Adjusted Diluted Earnings per Share		 $0.00 ($3.53) ($51,384,002.37) $0.06 ($2.01) ($1.89) ($1.83)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 17.58M 26.29M 26.39M 35.55M 47.07M 56.66M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($3.53) ($51,384,002.37) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.92M 21.66M 26.23M 41.35M 49.00M 59.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -29 -36 -27 -58 -73 -84
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Enliven Therapeutics

This table displays calculated financial ratios and metrics derived from Enliven Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 59,347,317.00 59,800,406.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 59,347,317.00 59,800,406.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.50 -0.40
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 -140.64% -142.08% -62.50% -16.46% -0.14% -5.69% -19.35% -16.86% 3.28% - 13.14%
EBIT Growth		 -121.89% -123.73% -58.29% -18.23% -11.27% -18.29% -22.13% -20.09% 7.03% - 12.34%
NOPAT Growth		 -121.77% -123.64% -58.28% -22.20% -11.63% -18.33% -21.96% -16.18% 7.29% - 12.21%
Net Income Growth		 -96.79% -102.83% -54.43% -19.31% -11.49% -19.67% -25.53% -26.99% 12.99% - 17.23%
EPS Growth		 84.40% 90.03% 32.50% 0.00% 5.88% -58.62% -5.56% -19.51% 33.33% - 33.33%
Operating Cash Flow Growth		 -146.53% -53.25% -12.08% -69.60% 23.29% -37.82% -3.28% 16.53% -8.91% - 20.04%
Free Cash Flow Firm Growth		 -17.85% -28.30% -41.93% 39.56% -20.55% -100.19% -48.29% -197.05% -14.06% - 8.72%
Invested Capital Growth		 -276.17% -179.33% -314.87% -765.37% -101.45% 49.99% 55.76% 72.96% 58.59% - 176.57%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 -25.25% 6.57% -8.68% 8.43% -7.70% 1.39% -22.72% 10.34% 10.86% - 19.43%
EBIT Q/Q Growth		 -20.50% 6.28% -14.29% 8.40% -13.41% 0.37% -18.01% 9.94% 12.21% - 18.85%
NOPAT Q/Q Growth		 -20.43% 6.26% -14.33% 5.33% -10.02% 0.64% -17.84% 9.81% 12.20% - 18.85%
Net Income Q/Q Growth		 -24.21% 6.74% -17.39% 12.26% -16.07% -0.10% -23.14% 11.24% 20.47% - 20.36%
EPS Q/Q Growth		 -24.39% 43.14% -86.21% 24.07% -17.07% 4.17% -23.91% 14.04% 34.69% - 15.56%
Operating Cash Flow Q/Q Growth		 -31.91% 21.47% -87.16% 12.53% 40.33% -41.09% -40.25% 29.30% 22.15% - -21.80%
Free Cash Flow Firm Q/Q Growth		 -0.44% 21.28% -42.80% 46.47% -100.35% -30.72% -5.78% -7.23% 23.07% - 11.89%
Invested Capital Q/Q Growth		 -253.23% -321.73% 60.99% -163.95% 53.61% -4.71% 65.50% -61.32% 28.95% - 131.91%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 101.18% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 85.61% 85.19% 87.49% 82.83% 85.78% 86.18% 89.93% 88.63% 80.28% - 84.92%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -38.72% -44.90% -26.14% -28.37% -30.98% -32.04% -31.30% -25.26% -25.43% - -26.64%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -8,638.44%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -38.72% -23.81% -26.14% -28.37% -30.98% -32.04% -31.30% -25.26% -25.43% - -26.64%
Return on Equity Simple (ROE_SIMPLE)		 -23.60% 0.00% -25.05% -27.16% -29.55% 0.00% -32.89% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -17 -16 -18 -17 -19 -19 -22 -20 -18 -24 -19
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.37% -2.10% -1.48% -0.92% -1.52% -1.54% -2.08% -1.33% -0.67% - -1.12%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.47% - - - -6.08% -7.70% -4.10% -3.69% -5.22% -4.30%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -24 -23 -26 -24 -27 -27 -32 -29 -25 -34 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 -24 -27 -24 -26 -26 -32 -28 -25 -34 -28
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.15 2.32 2.29 3.60 4.18 3.55 3.35 2.02 2.55 - 5.17
Price to Tangible Book Value (P/TBV)		 2.15 2.32 2.29 3.60 4.18 3.55 3.35 2.02 2.55 - 5.17
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 1,962.42
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.00 -1.03 -1.01 -1.01 -1.01 -1.02 -1.01 -1.01 -1.01 - -1.00
Leverage Ratio		 1.04 1.11 1.06 1.05 1.05 1.08 1.06 1.05 1.04 - 1.03
Compound Leverage Factor		 0.89 0.95 0.93 0.87 0.90 0.93 0.96 0.93 0.84 - 0.88
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 27.58 13.17 17.53 29.83 42.31 41.24 40.05 38.44 49.38 - 122.29
Noncontrolling Interest Sharing Ratio		 0.00% 46.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 22.24 10.28 13.47 14.39 17.44 19.99 21.06 32.58 32.95 - 40.32
Quick Ratio		 21.81 9.78 12.80 14.13 17.14 19.69 20.72 32.25 32.60 - 39.38
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -11 -16 -8.58 -17 -22 -24 -25 -20 -25 -22
Operating Cash Flow to CapEx		 -99,337.50% -89,157.14% -116,805.00% -1,021,750.00% -55,422.73% 0.00% -120,635.00% -12,271.22% 0.00% - 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.73 -7.30 -2.85 -7.51 -3.49 -3.65 -1.26 -2.03 -1.44 -3.02 0.96
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 -2.71 -4.68 -2.16 -8.64 -1.76 3.65 1.59 5.48 2.04 0.63 2.22
Enterprise Value (EV)		 299 317 407 787 915 786 675 494 735 - 1,892
Market Capitalization		 562 570 727 1,099 1,206 1,099 964 984 1,213 - 2,344
Book Value per Share		 $6.36 $5.97 $7.68 $6.48 $6.11 $6.34 $5.88 $9.95 $8.04 $7.74 $7.58
Tangible Book Value per Share		 $6.36 $5.97 $7.68 $6.48 $6.11 $6.34 $5.88 $9.95 $8.04 $7.74 $7.58
Total Capital		 262 246 318 305 288 310 288 488 476 460 453
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -263 -253 -321 -312 -292 -313 -290 -491 -478 -463 -452
Capital Expenditures (CapEx)		 0.02 0.01 0.02 0.00 0.02 0.00 0.02 0.14 -0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.95 -13 -8.39 -16 -12 -11 -9.21 -10 -9.53 -4.31 -0.75
Debt-free Net Working Capital (DFNWC)		 257 240 312 296 280 302 280 480 468 458 452
Net Working Capital (NWC)		 257 240 312 296 280 302 280 480 468 458 452
Net Nonoperating Expense (NNE)		 3.80 3.46 4.55 2.73 4.21 4.35 6.36 5.33 2.58 5.67 4.15
Net Nonoperating Obligations (NNO)		 -263 -253 -321 -312 -292 -313 -290 -491 -478 -463 -452
Total Depreciation and Amortization (D&A)		 -1.91 -1.71 -0.58 -0.53 0.79 1.06 0.03 0.15 -0.25 0.10 0.28
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.51) ($0.29) ($0.54) ($0.41) ($0.48) ($0.46) ($0.57) ($0.49) ($0.32) ($0.45) ($0.38)
Adjusted Weighted Average Basic Shares Outstanding		 41.03M 35.55M 42.05M 48.08M 48.27M 47.07M 50.05M 52.11M 62.09M 56.66M 62.80M
Adjusted Diluted Earnings per Share		 ($0.51) ($0.29) ($0.54) ($0.41) ($0.48) ($0.46) ($0.57) ($0.49) ($0.32) ($0.45) ($0.38)
Adjusted Weighted Average Diluted Shares Outstanding		 41.03M 35.55M 42.05M 48.08M 48.27M 47.07M 50.05M 52.11M 62.09M 56.66M 62.80M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 41.21M 41.35M 47.04M 47.24M 48.86M 49.00M 49.07M 59.24M 59.35M 59.80M 60.90M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -16 -18 -17 -19 -19 -22 -20 -18 -24 -19
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -14.14% -12.20% -1.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 -14.14% -12.20% -1.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Enliven Therapeutics (ELVN) has demonstrated a clear pattern over the last four years: ongoing quarterly net losses and operating cash burn, but periodic liquidity support from equity financings and investment maturities. Revenue remains minimal or non-existent in most quarters, while the balance sheet shows a sizable equity base helping to fund ongoing R&D and operations. Below are the 10 most important points, grouped by potential impact on investors. Positive items come first, followed by neutral, then negative items.

  • Big liquidity boost from equity financing in 2025 Q2: Issuance of Common Equity generated roughly $217 million in cash, with Net Cash From Continuing Financing Activities around $218.4 million.
  • Significant investment maturities boost cash in several quarters: In 2024–2025, several quarters benefited from maturities/sales of investments (e.g., Q4 2025 about $87.7M; Q3 2025 about $67.8M; Q4 2024 about $80.0M), providing notable cash inflows.
  • Strong near-term cash position from mid-2025: Cash & equivalents balance around $101.7M (Q3 2025), indicating a healthier near-term liquidity runway despite ongoing losses.
  • No meaningful revenue yet in recent years: Total revenue remains 0 in several quarters (e.g., Q3 2025 and many prior periods), highlighting ongoing reliance on financing and investment activity rather than operating cash flow.
  • Large common stock outstanding indicates dilution risk, but supports equity funding: Weighted shares outstanding are high (e.g., ~62–60 million to ~59–60 million across 2023–2025), and Basic/Diluted EPS are negative, signaling dilution to shareholders but enabling capital raises.
  • R&D and SG&A spend remains high and steady: Quarterly R&D and SGA expenses persist at elevated levels (e.g., 2025 Q4: RD $21.25M, SG&A $13.04M), which weighs on operating income but funds drug development efforts.
  • Persistent net losses each quarter: Net income (loss) continues negative across 2022–2025 (e.g., Q4 2025 net loss around $29.7M; Q1 2025 around $28.5M; Q2 2025 around $25.3M; Q3 2025 around $19.9M).
  • Ongoing operating cash burn: Net cash from continuing operating activities is consistently negative (e.g., Q4 2025 −$15.84M; Q3 2025 −$12.28M; Q2 2025 −$17.06M; Q1 2025 −$24.13M), indicating cash burn without operating liquidity offset.
  • Substantial investing outflows in some periods: Large net purchases of investments (e.g., Q2 2025 −$240.19M; Q3 2025 −$71.86M) offset by investment maturities, signaling heavy deployment of capital into securities rather than operating earnings.
  • Valuation and earnings per share remain negative: Across many quarters, Basic and Diluted EPS are negative (e.g., Q4 2025 EPS −$0.45; Q3 2025 EPS −$0.32; Q2 2025 EPS −$0.49; Q1 2025 EPS −$0.57), reflecting ongoing losses for common shareholders.
05/15/26 04:36 AM ETAI Generated. May Contain Errors.

Enliven Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Enliven Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Enliven Therapeutics' net income appears to be on an upward trend, with a most recent value of -$103.69 million in 2025, rising from -$23.46 million in 2019. The previous period was -$89.02 million in 2024. See Enliven Therapeutics' forecast for analyst expectations on what's next for the company.

Enliven Therapeutics' total operating income in 2025 was -$119.66 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $119.66 million

Over the last 6 years, Enliven Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Enliven Therapeutics' total liabilities were at $16.57 million at the end of 2025, a 4.1% increase from 2024, and a 278.1% increase since 2019.

In the past 6 years, Enliven Therapeutics' cash and equivalents has ranged from $4.94 million in 2019 to $124.12 million in 2024, and is currently $98.90 million as of their latest financial filing in 2025.

Over the last 6 years, Enliven Therapeutics' book value per share changed from -69.54 in 2019 to 7.74 in 2025, a change of -111.1%.


Related Companies

Financial statements for NASDAQ:ELVN last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel